Director Frederic Moll of PROCEPT BioRobotics (PRCT) granted RSUs and options

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp director Frederic H. Moll received new equity awards as part of his compensation. He acquired 3,315 restricted stock units, each representing one future share of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service.

He was also granted a stock option for 5,853 shares of common stock at an exercise price of $28.78 per share, vesting on the same schedule. Following the RSU award, Moll directly holds 866,474 shares of common stock, indicating this is a routine, compensation-related equity grant rather than an open-market purchase or sale.

Insights

Equity compensation analyst

Director received routine RSU and option grants as equity compensation.

Director Frederic H. Moll was granted 3,315 restricted stock units and an option for 5,853 shares at an exercise price of $28.78 per share. Both awards vest in full after roughly one year or at the next annual meeting, subject to continued service.

These awards are compensation-related, reflected by transaction code A (grant/award acquisition) and a zero-dollar grant price. They do not represent open-market buying or selling, so they carry limited signaling value about the director’s view of the stock.

After the grant, Moll directly holds 866,474 common shares, and 5,853 options from this award. Subsequent filings may detail future vesting or any exercises, which would show how these compensation awards translate into actual share ownership over time.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MOLL FREDERIC H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,853	$0.00	--
Grant/Award	Common Stock	3,315	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,853 shares (Direct, null); Common Stock — 866,474 shares (Direct, null)

Footnotes (1)

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Key Figures

RSU grant: 3,315 units Option grant size: 5,853 shares Option exercise price: $28.78 per share +2 more

5 metrics

RSU grant 3,315 units Restricted stock units granted to director on June 9, 2026

Option grant size 5,853 shares Stock option (right to buy) granted June 9, 2026

Option exercise price $28.78 per share Exercise price for 5,853-share stock option

Shares held after grant 866,474 shares Common stock directly held by Frederic Moll after RSU grant

Option expiration June 8, 2036 Expiration date of 5,853-share stock option

Key Terms

restricted stock units (RSUs), Stock Option (Right to Buy), exercise price, annual meeting

4 terms

restricted stock units (RSUs) financial

"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Stock Option (Right to Buy) financial

"The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date..."

exercise price financial

"The Stock option was granted on June 9, 2026, and vests in full... with a conversion or exercise price of 28.7800."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting financial

"The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting..."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOLL FREDERIC H

(Last) (First) (Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE CALIFORNIA 95134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A(1)		3,315	A	$0	866,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.78	06/09/2026		A		5,853		(2)	06/08/2036	Common Stock	5,853	$0	5,853	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

2. The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Remarks:

	/s/ Jonathan Stone, Attorney-in-Fact for Frederic Moll	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did PROCEPT BioRobotics (PRCT) director Frederic Moll receive?

Director Frederic H. Moll received 3,315 restricted stock units and a stock option covering 5,853 shares. The option has an exercise price of $28.78 per share and both awards vest in full after about one year or at the next annual meeting, subject to continued service.

Are Frederic Moll’s recent PROCEPT BioRobotics (PRCT) transactions open-market buys or sells?

The transactions are not open-market buys or sells. They are compensation-related grants: 3,315 restricted stock units and a 5,853-share stock option, both reported with transaction code A for a grant or award, and a zero-dollar grant price, indicating standard equity compensation rather than trading activity.

What are the vesting terms for Frederic Moll’s new PROCEPT BioRobotics (PRCT) RSUs and options?

Both the 3,315 restricted stock units and the 5,853-share stock option vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, provided Frederic Moll continues serving through the applicable vesting date.

How many PROCEPT BioRobotics (PRCT) shares does Frederic Moll hold after these grants?

Following the grant of 3,315 restricted stock units, Frederic Moll directly holds 866,474 shares of PROCEPT BioRobotics common stock. He also holds a newly granted stock option for 5,853 shares at an exercise price of $28.78 per share, which will vest in full under the stated schedule.

What does transaction code A mean in Frederic Moll’s PROCEPT BioRobotics (PRCT) Form 4?

Transaction code A on the Form 4 indicates a grant, award, or other acquisition rather than an open-market trade. For Frederic Moll, it reflects the award of 3,315 restricted stock units and a 5,853-share stock option as part of his director equity compensation package.